Deutsches Arzteblatt international · 2026
Incidence and Survival Trends in Cancer of Unknown Primary (CUP): An Analysis From the North Rhine-Westphalia Cancer Registry, 2007-2023.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zaun Gregor, Kalkavan Halime, Schuler Martin, Lueong Smiths, Mavroeidi Ilektra Antonia, Wiesweg Marcel, Theurer Sarah, Metzenmacher Martin, Zaun Yasmin, Guberina Maja, Kasper-Virchow Stefan, Stang Andreas, Wellmann Ina, Kajüter Hiltraud
Аннотация
BACKGROUND: The term "cancer of unknown primary" (CUP) refers to metastatic tumors whose origin has not been identified even after a comprehensive diagnostic evaluation. Patients with CUP generally have an unfavorable prognosis. We analyzed CUP incidence and survival trends in the German state of North Rhine-Westphalia (NRW) over a 17-year period.
METHODS: We carried out a population-based analysis of data from the NRW Cancer Registry (2007-2023). CUP cases were identified for inclusion in accordance with the current ESMO criteria; DCO cases ("death certificate only") were excluded. Age-standardized incidence rates were calculated in reference to the old European standard population. Five-year relative survival (RS) was determined with period analysis for 2010-2015 and 2018-2023, and subgroup analyses were performed.
RESULTS: Out of 48 574 cases of CUP that were noted in the registry, 21 085 were found to satisfy the current ESMO criteria. The age-standardized incidence of CUP fell markedly, from 6.5 per 100 000 person-years in 2007 to 2.2 per 100 000 person-years in 2023 (average annual percentage change [AAPC], -5.45%; 95% confidence interval [-6.49; -4.40]), while five-year RS rose from 14.7% to 21.8%. Of all types of CUP, squamous cell carcinoma was associated with the highest RS (42.8%), and adenocarcinoma and undifferentiated carcinoma with the lowest (14-15%). RS was lower in older patients.
CONCLUSION: The marked decline in CUP incidence and the moderate improvement in its survival rate likely reflect advances in diagnosis and subgroup-specific treatment. CUP still carries a generally unfavorable prognosis, and more research is needed in molecular diagnosis and targeted therapies.
METHODS: We carried out a population-based analysis of data from the NRW Cancer Registry (2007-2023). CUP cases were identified for inclusion in accordance with the current ESMO criteria; DCO cases ("death certificate only") were excluded. Age-standardized incidence rates were calculated in reference to the old European standard population. Five-year relative survival (RS) was determined with period analysis for 2010-2015 and 2018-2023, and subgroup analyses were performed.
RESULTS: Out of 48 574 cases of CUP that were noted in the registry, 21 085 were found to satisfy the current ESMO criteria. The age-standardized incidence of CUP fell markedly, from 6.5 per 100 000 person-years in 2007 to 2.2 per 100 000 person-years in 2023 (average annual percentage change [AAPC], -5.45%; 95% confidence interval [-6.49; -4.40]), while five-year RS rose from 14.7% to 21.8%. Of all types of CUP, squamous cell carcinoma was associated with the highest RS (42.8%), and adenocarcinoma and undifferentiated carcinoma with the lowest (14-15%). RS was lower in older patients.
CONCLUSION: The marked decline in CUP incidence and the moderate improvement in its survival rate likely reflect advances in diagnosis and subgroup-specific treatment. CUP still carries a generally unfavorable prognosis, and more research is needed in molecular diagnosis and targeted therapies.